Go to the list of all blogs
Anna G's Avatar
published in Blogs
Jan 30, 2021
TickeronGET DAILY SIGNALS
Twitter (TWTR, $50.52) shares rating upgraded by KeyBanc

Twitter (TWTR, $50.52) shares rating upgraded by KeyBanc

Twitter  got  a rating upgrade from analysts at KeyBanc, on expected  long-term revenue growth.

Analysts at KeyBanc boosted their rating on the microblogging company’s shares to overweight (from sector weight), saying they expected long-term revenue growth to be driven by the platform’s improvement in  the experience for advertisers and users.

"Our view is that execution is improving, and the combination of a cyclical ad recovery and new products creates potential for revenue to outpace our above-consensus revenue estimates in 2021 and 2022," KeyBanc analysts wrote in a research note.

KeyBank forecasts more than +20% annual growth in Twitter revenue. The analysts affirmed a price target of $65 on Twitter's shares.

Related Ticker: TWTR
Related Portfolios: TECHNOLOGY ETFs
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a global platform for public self expression and conversation in real time

Industry InternetSoftwareServices

Industry
Internet Software Or Services
Address
1355 Market Street
Phone
+1 415 222-9670
Employees
7500
Web
https://www.twitter.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
AstraZeneca reported Q1 2026 total revenue of $15.3 billion, up 8% at constant exchange rates (CER, adjusting for currency fluctuations), beating consensus estimates around $14.8 billion. Core earnings per share (EPS) rose 5% to $2.58 at CER, amid a 12% increase in core operating profit.
Consensus estimates call for Q3 FY2026 revenue of approximately $3.37 billion, in line with the company's guidance midpoint of $3.35 billion. Non-GAAP earnings per share (EPS) expected at $9.16, edging above the guided midpoint of $9.08.